Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nomenclature and Definition of Metabolic-Associated Fatty Liver Disease: A Consensus From the Middle East and North Africa Publisher Pubmed



Shiha G1, 2 ; Alswat K3 ; Al Khatry M4 ; Sharara AI5 ; Ormeci N6 ; Waked I7 ; Benazzouz M8 ; Alali F9 ; Hamed AE10 ; Hamoudi W11 ; Attia D12 ; Derbala M13 ; Sharafeldin M14 ; Albusafi SA15 Show All Authors
Authors
  1. Shiha G1, 2
  2. Alswat K3
  3. Al Khatry M4
  4. Sharara AI5
  5. Ormeci N6
  6. Waked I7
  7. Benazzouz M8
  8. Alali F9
  9. Hamed AE10
  10. Hamoudi W11
  11. Attia D12
  12. Derbala M13
  13. Sharafeldin M14
  14. Albusafi SA15
  15. Zaky S16
  16. Bamakhrama K17
  17. Ibrahim N18
  18. Ajlouni Y19
  19. Sabbah M20
  20. Salama M7
  21. Anushiravani A21
  22. Afredj N22
  23. Barakat S23
  24. Hashim A24
  25. Fouad Y25
  26. Soliman R1, 26
Show Affiliations
Authors Affiliations
  1. 1. Egyptian Liver Research Institute and Hospital, Mansoura, Egypt
  2. 2. Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
  3. 3. Liver Disease Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
  4. 4. Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, United Arab Emirates
  5. 5. Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  6. 6. Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey
  7. 7. Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El Kom, Egypt
  8. 8. Service of Medicine C, Centre Hospitalier Universaitaire Ibn Sina, Rabat, Morocco
  9. 9. Department of Gastroenterology, Royal Hayat Hospital, Faculty of Medicine, Kuwait University, Kuwait
  10. 10. Department of Internal Medicine, Hepatology, and Diabetes, Egyptian Military Medical Academy, Cairo, Egypt
  11. 11. Internal Medicine Department, Al-Bashir Hospital, Amman, Jordan
  12. 12. Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt
  13. 13. Gastroenterology and Hepatology Department, Hamad Medical Corporation, Doha, Qatar
  14. 14. Department of Gastroenterology and Hepatology, Faculty of Medicine, Tanta University, Tanta, Egypt
  15. 15. Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
  16. 16. Department of Hepatogastroenterology and Infectious Diseases, Al-Azhar University, Cairo, Egypt
  17. 17. Department of Gastroenterology, Rashid Hospital, Dubai, United Arab Emirates
  18. 18. Department of Gastroenterology and Hepatology, Al-Kalamoon University, Damascus, Syrian Arab Republic
  19. 19. Department of Internal Medicine, Royal Medical Services, King Hussein Medical City, Amman, Jordan
  20. 20. Department of Gastroenterology, Habib Thameur Hospital, Tunis, Tunisia
  21. 21. Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  22. 22. Hepatology Unit, Department of Medicine Mustapha Hospital, Algiers, Algeria
  23. 23. National Center for Gastrointestinal and Liver Diseases, Ibn Sina Hospital, Ministry of Health, Khartoum, Sudan
  24. 24. Department of Internal Medicine, Jeddah University, Jeddah, Saudi Arabia
  25. 25. Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Minya University Hospitals, Minya, Egypt
  26. 26. Tropical Medicine Department, Faculty of Medicine, Port Said University, Port Said, Egypt

Source: The Lancet Gastroenterology and Hepatology Published:2021


Abstract

With the increasing prevalence of obesity and type 2 diabetes, fatty liver disease associated with metabolic dysfunction is a global health problem, especially because it is one of the earliest consequences of obesity and it precedes diabetes development. Fatty liver disease associated with metabolic dysfunction is of particular concern in the Middle East and north Africa, where its prevalence is greater than that in the rest of the world. Despite the magnitude of the problem, no regional guidelines have been developed to address this disease. This Review describes suggestions of redefining fatty liver disease associated with metabolic dysfunction, including its terminology and criteria for diagnosis. Experts have raised serious concerns on the current nomenclature, which labels the disease as non-alcoholic fatty liver disease (NAFLD), and its diagnostic criteria. The panel reached a consensus that the disease should be renamed as metabolic-associated fatty liver disease (MAFLD) and that the disease should be diagnosed by positive criteria. The aim is now to work with authorities across the region to implement these proposed changes and reflect them in health-care policy and to improve health care for patients in this region. © 2021 Elsevier Ltd
Other Related Docs
11. Covid-19 and Mafld/Nafld: An Updated Review, Frontiers in Medicine (2023)